MYOS Appoints Andrew J. Einhorn as Chief Financial Officer
Published: Oct 19, 2012
CEDAR KNOLLS, NJ--(Marketwire - October 18, 2012) -
MYO-T12 Product Website
Mr. Einhorn has extensive knowledge of the pharmaceutical industry's financial operations, due to his previous experience in senior management positions at other pharmaceutical companies. Einhorn most recently served as Executive Vice President and Chief Financial Officer at Oceana Therapeutics, Inc. up until its sale to Salix Pharmaceuticals in 2011. Prior to that, Mr. Einhorn served as Executive Vice President and CFO of Esprit Pharma, Inc., where he was responsible for the company's finances and was actively involved in its sale to Allergan Inc. Mr. Einhorn also served as Executive Vice President and CFO at ESP Pharma, Inc., where he managed the company's finances until its sale to Protein Design Labs Inc. for approximately a half-billion dollars.
"With such a successful track record as the financial manager of other pharmaceutical companies, we are thrilled to have Andrew Einhorn on board at MYOS," said Peter Levy, Chief Operating Officer of MYOS. "Andrew's experience and financial acumen make him a perfect choice to guide us through the expansion of our business, and we are excited to work with him." Mr. Einhorn stated, "I was attracted to a terrific product opportunity and the team at MYOS and I look forward to helping guide the company's business strategy and positioning it for future growth."
Prior to his work in the pharmaceutical industry, Mr. Einhorn spent nearly twenty years in the banking industry, where he served as Managing Director with Credit Lyonais Securities, PNC Capital Markets, Bankers Trust Company, Chase Securities and Chase Manhattan Bank. Mr. Einhorn started his career with Touche Ross & Company, where he served as a senior accountant responsible for managing audits for healthcare and other industry clients, giving him a different perspective of the finances of healthcare companies.
Additional information regarding this appointment is available in a Form 8-K filed by MYOS with the Securities and Exchange Commission on October 15, 2012.
About MYOS Corporation
MYOS is a development stage company focused on the discovery, development and commercialization of therapeutic products that improve muscle health and performance. MYOS is the owner of MYO-T12, the world's first clinically demonstrated myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. MYO-T12 is manufactured to optimize biological activity, which MYOS believes has the potential to redefine existing standards of physical health and wellness enhancement. For more information on MYO-T12 and to discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com.
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.